Puma Biotechnology/$PBYI
Puma Biotechnology shares fall after Q3 revenue missed expectations, with weaker sequential NERLYNX demand and lower China royalties from generic competition weighing despite an earnings beat.
4 hours agoLightyear AI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
- Ticker
- $PBYI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 179
- Headquarters
- Los Angeles, United States
- Website
- www.pumabiotechnology.com
PBYI Metrics
BasicAdvanced
$504M
19.40
$0.50
1.23
-
Price and volume
Market cap
$504M
Beta
1.23
52-week high
$11.50
52-week low
$4.58
Average daily volume
364K
Financial strength
Current ratio
2.912
Quick ratio
2.568
Long term debt to equity
0.032
Total debt to equity
0.035
Interest coverage (TTM)
8.65%
Profitability
EBITDA (TTM)
40.115
Gross margin (TTM)
74.86%
Net profit margin (TTM)
11.56%
Operating margin (TTM)
13.16%
Effective tax rate (TTM)
14.28%
Revenue per employee (TTM)
$1,290,000
Management effectiveness
Return on assets (TTM)
9.82%
Return on equity (TTM)
21.97%
Valuation
Price to earnings (TTM)
19.402
Price to revenue (TTM)
2.139
Price to book
3.6
Price to tangible book (TTM)
4.89
Price to free cash flow (TTM)
12.045
Free cash flow yield (TTM)
8.30%
Free cash flow per share (TTM)
0.811
Growth
Revenue change (TTM)
-2.85%
Earnings per share change (TTM)
-48.22%
3-year revenue growth (CAGR)
0.16%
3-year earnings per share growth (CAGR)
101.58%
10-year earnings per share growth (CAGR)
-24.17%
What the Analysts think about PBYI
Analyst ratings (Buy, Hold, Sell) for Puma Biotechnology stock.
Analyst projections of the future price of Puma Biotechnology stock.
Bulls say / Bears say
NERLYNX demand is growing modestly: third-quarter net product revenue rose to $54.1 million from $51.9 million a year earlier, and revenue for the first nine months also increased. Puma says US demand was higher year on year. (Puma Biotechnology)
Puma has a stronger financial base to fund its trials: it generated $31.6 million of operating cash in the first nine months, held $108.5 million in cash and marketable securities at September-end, and has repaid its debt. (Puma Biotechnology, Puma Biotechnology)
Alisertib could broaden Puma beyond NERLYNX, with Phase II studies under way in breast and small-cell lung cancer. Updated breast-cancer data are due in December, while a second lung study has begun. (Puma Biotechnology, Puma Biotechnology)
Recent US sales trends look weaker than the year-on-year growth suggests: NERLYNX sales slipped to $50.6 million from $53.6 million in the prior quarter, new prescriptions fell 13% sequentially, and third-quarter net income declined to $6.0 million from $8.8 million a year earlier. (The Motley Fool, Puma Biotechnology)
Generic competition in China is cutting into royalties: Puma recorded a $2.1 million reduction after generics reached a market-share threshold, and its royalty rate there will be lower going forward. It reduced its 2026 royalty outlook to $18–$19 million from $19–$22 million. (Puma Biotechnology)
Alisertib remains a clinical bet, not an established growth source: its programmes are still in Phase II, and Puma has amended the breast study to continue at only two dose levels. More follow-up data are needed before its efficacy and commercial potential are clear. (The Motley Fool, Puma Biotechnology)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
PBYI Financial Performance
Revenues and expenses
PBYI Earnings Performance
Company profitability
Upcoming events
No upcoming events
PBYI News
AllArticlesVideos
Funds containing PBYI
Fund name | Fund size | $PBYI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.